| Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. | |
| | |
MedLine Citation:
|
PMID: 21219411 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To assess pharmacokinetics and pharmacodynamics of a 10 mg intravenous sildenafil bolus in pulmonary arterial hypertension (PAH) patients stabilized on 20 mg sildenafil orally three times daily. METHODS: Pharmacokinetic parameters were calculated using noncompartmental analysis. RESULTS: After an acute increase, plasma concentrations stabilized within the range reported previously for a 20 mg oral tablet. At 0.5 h, mean ± SD changes from baseline were -8.4 ± 11.7 mmHg (systolic pressure), -2.6 ± 7.3 mmHg (diastolic pressure) and -3.5 ± 10.4 beats min(-1) (heart rate). There was no symptomatic hypotension. CONCLUSIONS: Although further research is warranted, a 10 mg sildenafil intravenous bolus appears to provide similar exposure, tolerability and safety to the 20 mg tablet. |
| | |
Authors:
|
Jean-Luc Vachiery; Sandrine Huez; Hunter Gillies; Gary Layton; Naoto Hayashi; Xiang Gao; Robert Naeije |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: 71 ISSN: 1365-2125 ISO Abbreviation: Br J Clin Pharmacol Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-11 Completed Date: 2011-03-29 Revised Date: 2012-02-01 |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 289-92 Citation Subset: IM |
Copyright Information:
|
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. |
Affiliation:
|
Pulmonary Hypertension and Heart Failure Clinic, Hôpital Erasme, Brussels, Belgium. jvachier@ulb.ac.be |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00800592 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adolescent Adult Aged Antihypertensive Agents / administration & dosage*, adverse effects, blood Drug Administration Schedule Female Humans Hypertension, Pulmonary / blood, drug therapy* Infusions, Intravenous Male Middle Aged Phosphodiesterase 5 Inhibitors / administration & dosage, adverse effects, blood Piperazines / administration & dosage*, adverse effects, blood Purines / administration & dosage, adverse effects, blood Sulfones / administration & dosage*, adverse effects, blood Vasodilator Agents / administration & dosage*, adverse effects, blood Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Phosphodiesterase 5 Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 0/Vasodilator Agents; 139755-83-2/sildenafil |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An investigation into the effect of advice from the Scottish Medicines Consortium on the use of medi...
Next Document: A point prevalence survey of antibiotic prescriptions: benchmarking and patterns of use.